Project Grant R21NS141767
Award Date
9/9/24
Completion Date
8/31/26
Dollars Obligated
$74K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
This federal Project Grant award of $238,500 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research conducted by the University of California, San Diego (UCSD) to develop a new phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic for treating Alzheimer's disease (AD). The research aims to create a highly effective PMO that can...
This $897,250 federal project grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports a comprehensive research program on the role of biomolecular condensates in neurological diseases. The award period is from May 1, 2025 to April 30, 2033. The research program aims to address key questions regarding the physiological functions of biomolecular condensates,...
This federal Project Grant award, valued at $129,717.00 and awarded on January 20, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the role of neutrophil heterogeneity and molecular mechanisms in driving amyotrophic lateral sclerosis (ALS). The research aims to identify subpopulations of neutrophils and associated mechanisms...
This Project Grant award of $374,349 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the development and optimization of a new animal model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The goal is to create a mouse model that accurately recapitulates the human disease spectrum by incorporating an acetylation-mimicking...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Case Western Reserve University provides $442,750 to develop synthetic replicas of TDP-43 protein filaments associated with frontotemporal dementia and amyotrophic lateral sclerosis. The goal is to establish in vitro conditions for generating amyloid fibrils with structures identical to brain-derived TDP-43 filaments, which would enable mechanistic studies on disease-relevant aggregation pathways...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $236,668.00 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the impact of the C9ORF72-associated poly (GR) protein on the structure and function of the BAF chromatin remodeling complex. The research aims to...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $432,802 to Pennsylvania State University, doing business as Penn State Milton S. Hershey Medical Center, to conduct research on gene expression changes in C9ORF72 frontotemporal dementia (FTD) using Drosophila and human model systems. The research aims to cross-validate "C9...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded Aquinnah Pharmaceuticals, Inc. a $1,499,212 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to develop a novel oral brain penetrant therapeutic for amyotrophic lateral sclerosis (ALS). The project aims to manufacture the therapeutic candidate, conduct IND-enabling studies, and engage in a pre-IND meeting with the FDA. The goal is to create the first effective...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $460,625.00 to the University of Massachusetts Medical School (UMass Medical) from June 1, 2025 to May 31, 2027. The grant supports research to investigate the role of TDP-43 citrullination in the pathogenesis of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The...